Adam Platt-澳门在线赌城娱乐

As VP of Translational Science and Experimental Medicine (TSEM) for Respiratory and Immunology (R&I) at AstraZeneca, I am part of the R&I leadership team spanning the UK, Sweden and US. I designed and launched TSEM to provide a roadmap from novel targets to disease pathology and biomarkers, with precision medicine from the start, emphasising the importance of understanding the heterogeneity of common chronic disease.

Already we have a number of molecules in clinical development where we are actively developing what will be some of the first examples of precision medicine for common chronic disease.

Previously, as Global Head of Genomics Portfolio in AstraZeneca’s Centre for Genomics Research, I played a pivotal role in securing the $400+ million investment to integrate genome sequence and clinical data from up to two million patients. Other business-critical deliveries have included AstraZeneca’s first respiratory diagnostic achieving EU CE-IVD certification in December 2018, and FDA clearance for a Point of Care (PoC) serum uric acid meter to monitor the effectiveness of urate lowering therapies.

I completed my PhD in molecular genetics from the University of Liverpool and I have published over 40 peer-reviewed articles, most recently in the New England Journal of Medicine, Nature and Nature Reviews Drug Discovery.

It is a privilege to have the opportunity to apply strong science with many of the talented scientists and teams at AstraZeneca to bring life changing medicines to improve patients’ lives.

Adam Platt, PhD VP and Head of Translational Science and Experimental Medicine, Respiratory & Immunology, AstraZeneca

Award

2017 CEO Award for Respiratory PoC Diagnostic

Award

2017 CEO Award for Best-of-the-Best, Achieve Scientific Leadership

Award

2016 Senior Scientist IMED Award – Development of Respiratory PoC Diagnostic

Award

2016 IMED Recognition Award – Genomic Strategy

Developing a prototype PoC test for eosinophilic respiratory disease, which will become AstraZeneca’s first POC diagnostic for respiratory disease.

Designing and launching Target and Translational Science, a new organisation in IMED RIA, providing a roadmap from target modulation to disease pathology.

Co–establishing the AstraZeneca Genomics Initiative and Centre for Genomics Research (CGR). This initiative involves integrating genome sequence and clinical data from up to two million patients from AstraZeneca’s clinical trials and key international partnerships.

Featured publications

Diagnostic utility of exome sequencing for kidney disease.

Drug development in the era of precision medicine.

An analytical comparison between point-of-care uric acid testing meters.

Rheumatoid arthritis: a case for personalized health care?

A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.

Translational biomarkers and ex vivo models of joint tissues as a translational tool for drug development in rheumatoid arthritis.

Serological biomarkers of joint tissue turnover predict tocilizumab response at baseline.

IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis.

Serological identification of fast progressors of structural damage with rheumatoid arthritis.

Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis.

IL-6 Receptor Inhibition Positively Modulates Bone Balance in Rheumatoid Arthritis Patients with an Inadequate Response to Anti-Tumor Necrosis Factor Therapy: Biochemical Marker Analysis of Bone Metabolism in the tocilizumab RADIATE Study.

Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab.

The insertion of two amino acids into a transcriptional inducer converts it into a galactokinase.

The yeast galactose genetic switch is mediated by formation of a Gal4p/Gal80p/Gal3p complex.

Nitrogen metabolite repression involves the C-terminus and the GATA domain of the Aspergillus transcription factor AREA and the 3'-untranslated region of its mRNA.

Veeva ID: Z4-51856
Date of preparation: January 2023